Campylobacter trial begins
Following Investigational New Drug (IND) approval by the US FDA, Ace
Biosciences and US Naval Medical Research Centre begin a Campylobacter trial.
The US Naval Medical Research Center and the infectious diseases company,
, have announced that their first subjects are
being dosed in a trial to establish a vaccine challenge model for the evaluation
vaccines. This includes ACE BioSciences' leading
product, the Travellers' Diarrhoea (TD) vaccine ACE393
ACE393 is on track to become the world's first commercial vaccine for
Travellers' Diarrhoea caused by Campylobacter infection. The aim of the
challenge trial is to establish the appropriate dose of bacteria needed to
produce a response that is representative of the natural disease state, whilst
posing minimal risk to volunteers.
It is anticipated that the trial will be completed in the second half of
To comment, login here
Or register to be able to comment.